KYMR Q2 2022 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-37.8% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$41M-354.4% margin

Net Income

-$40M-349.6% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

+19.7%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$523M

Total Liabilities

$125M

Stockholders' Equity

$398M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$19M	-37.8%
Gross Profit	$12M	$19M	-37.8%
Operating Income	-$41M	-$25M	-65.0%
Net Income	-$40M	-$25M	-63.2%